Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 9/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119388 | 1.00 | KMT2A (0.44) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL4833369 | 1.00 | KMT2A (0.44) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL5119391 | 1.00 | KMT2A (0.44) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL4662966 | 0.92 | KMT2A (0.45) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL4662963 | 0.92 | KMT2A (0.45) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL5117293 | 0.92 | KMT2A (0.45) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL14307924 | 0.89 | KMT2A (0.47) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL14278245 | 0.87 | KMT2A (0.45) | KMT2AMEN1TRPA1CCR1CACNA1B | |
| SCHEMBL5119468 | 0.83 | KMT2A (0.49) | KMT2AMEN1CCR1 | |
| SCHEMBL5119477 | 0.83 | KMT2A (0.49) | KMT2AMEN1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007787-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | KMT2A 3407/4885MEN1 2302/4885TRPA1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.